Tigecycline



Indications and Reactions:

Role Indications Reactions
Primary
Pneumonia 12.6%
Acinetobacter Infection 8.8%
Klebsiella Infection 6.7%
Cellulitis 6.5%
Constipation 6.5%
Hypertension 6.5%
Sepsis 6.3%
Pathogen Resistance 4.8%
Abdominal Infection 4.6%
Candidiasis 4.4%
Osteomyelitis 4.0%
Bacteraemia 3.8%
Staphylococcal Infection 3.8%
Peritonitis 3.6%
Abdominal Abscess 3.1%
Infection 3.1%
Multiple-drug Resistance 2.9%
Pain 2.9%
Soft Tissue Infection 2.7%
Analgesic Effect 2.5%
Death 13.3%
Drug Ineffective 10.8%
Vomiting 9.6%
Pancreatitis 9.0%
Infection 6.0%
Pathogen Resistance 6.0%
Clostridial Infection 4.8%
Thrombocytopenia 4.8%
Jaundice 4.2%
Renal Failure Acute 4.2%
Diarrhoea 3.6%
Sepsis 3.6%
Drug Resistance 3.0%
Septic Shock 3.0%
Electrocardiogram Qt Prolonged 2.4%
Multi-organ Failure 2.4%
Pancreatitis Necrotising 2.4%
Pulmonary Embolism 2.4%
Thrombocythaemia 2.4%
Lung Abscess 1.8%
Secondary
Pneumonia 10.1%
Acinetobacter Infection 9.3%
Abdominal Infection 9.0%
Klebsiella Infection 8.7%
Bacteraemia 6.6%
Sepsis 5.7%
Drug Use For Unknown Indication 5.4%
Antibiotic Therapy 5.2%
Staphylococcal Infection 5.2%
Multiple-drug Resistance 4.4%
Aspergillosis 3.8%
Product Used For Unknown Indication 3.5%
Urinary Tract Infection 3.4%
Enterobacter Infection 3.2%
Pathogen Resistance 3.0%
Blood Cholesterol Increased 2.8%
Muscle Spasms 2.8%
Staphylococcal Bacteraemia 2.7%
Autoimmune Hepatitis 2.6%
Peritonitis 2.6%
Death 21.8%
Drug Ineffective 12.6%
Multi-organ Failure 7.5%
Respiratory Failure 6.9%
Pathogen Resistance 6.3%
Infection 5.7%
Septic Shock 5.2%
Shock Haemorrhagic 4.6%
Sepsis 4.0%
Drug Resistance 2.9%
Pneumonia Klebsiella 2.9%
Rash Macular 2.9%
Acinetobacter Infection 2.3%
Clostridial Infection 2.3%
Infusion Site Irritation 2.3%
Klebsiella Bacteraemia 2.3%
Splenic Infarction 2.3%
International Normalised Ratio Increased 1.7%
Jaundice 1.7%
Pancreatitis 1.7%
Concomitant
Product Used For Unknown Indication 44.3%
Drug Use For Unknown Indication 17.8%
Prophylaxis 4.2%
Acute Myeloid Leukaemia 3.9%
Infection 3.2%
Acute Lymphocytic Leukaemia 3.0%
Pneumonia 3.0%
Pain 2.4%
Hypertension 2.1%
Peritonitis 2.1%
Antibiotic Prophylaxis 1.8%
Febrile Neutropenia 1.8%
Sepsis 1.8%
Infection Prophylaxis 1.4%
Post Procedural Infection 1.4%
Pyrexia 1.4%
Stem Cell Transplant 1.4%
Multiple Myeloma 1.3%
Prophylaxis Against Graft Versus Host Disease 1.1%
Atypical Mycobacterial Infection 1.0%
Sepsis 17.5%
Weight Decreased 12.7%
Treatment Failure 10.3%
Drug Ineffective 6.3%
Renal Failure Acute 6.3%
Septic Shock 4.8%
Postoperative Wound Infection 4.0%
Renal Failure 4.0%
Leukopenia 3.2%
Pancreatitis 3.2%
Rhabdomyolysis 3.2%
Urinary Retention 3.2%
Vomiting 3.2%
White Blood Cell Count Decreased 3.2%
White Blood Cell Count Increased 3.2%
Apnoea 2.4%
Death 2.4%
Hepatotoxicity 2.4%
Infection 2.4%
Multi-organ Failure 2.4%
Interacting
Immunosuppression 35.3%
Enterococcal Infection 11.8%
Osteomyelitis Chronic 11.8%
Prophylaxis Against Transplant Rejection 11.8%
Sepsis 11.8%
Anaesthesia 5.9%
Pneumonia Staphylococcal 5.9%
Septic Shock 5.9%
Neurological Symptom 33.3%
Blood Creatinine Increased 16.7%
Immunosuppressant Drug Level Increased 16.7%
Pancreatitis Necrotising 16.7%
Platelet Count Decreased 16.7%